L’Alliance Promotion Microbiote accueille Ferring Pharmaceuticals, Pelican Health et Polepharma en tant que nouveaux membres
November 09, 2023 10:00 ET
|
ALLIANCE PROMOTION MICROBIOTE
Lyon- France – 9 novembre 2023 – L’Alliance Promotion Microbiote (APM), acteur majeur dédié au développement, à la production et à la commercialisation d’innovations thérapeutiques basées sur le...
Alliance Promotion Microbiote To Welcome Ferring Pharmaceuticals, Pelican Health and Polepharma as New Members
November 09, 2023 10:00 ET
|
ALLIANCE PROMOTION MICROBIOTE
Lyon – France, November 9th, 2023 – Alliance Promotion Microbiote (APM), a leading player dedicated to the development, the production, and the commercialization of therapeutic innovations based on...
The Biocodex Microbiota Foundation calls for Canadian proposals to study the microbiome’s role in health and diseases
July 31, 2023 16:20 ET
|
Biocodex Canada
The Biocodex Microbiota Foundation is looking for academics and scientists in Canada to apply for a €25,000 research grant aimed at helping advance the study of the gut microbiome MONTREAL, July 31,...
EnteroBiotix appoints Elmar Schnee as Executive Chairman
July 17, 2023 03:00 ET
|
EnteroBiotix
GLASGOW, Scotland, July 17, 2023 (GLOBE NEWSWIRE) -- EnteroBiotix Limited (“EBX”), a clinical stage company with the premier platform for full-spectrum microbiome therapeutics, today announced the...
Summit Therapeutics Inc. Reports Financial Results and Operational Progress for the Third Quarter and Nine Months Ended September 30, 2022
November 09, 2022 08:30 ET
|
Summit Therapeutics Inc.
Menlo Park, California, Nov. 09, 2022 (GLOBE NEWSWIRE) -- Summit Therapeutics Inc. (NASDAQ: SMMT) ("Summit," "we," or the "Company") today reports its financial results and provides an update on...
Summit Therapeutics Presents Ri-CoDIFy Trial Results for Microbiome-Sparing Ridinilazole at IDWeek 2022
October 20, 2022 17:15 ET
|
Summit Therapeutics Inc.
Ridinilazole resulted in a 53% relative risk reduction in recurrence of C. difficile infection compared to treatment with vancomycin Ridinilazole preserved the gut microbiome compared to...
Summit Therapeutics to Present Ri-CoDIFy Trial Results for Microbiome-Sparing Ridinilazole at IDWeek 2022
October 13, 2022 08:00 ET
|
Summit Therapeutics Inc.
Menlo Park, California, Oct. 13, 2022 (GLOBE NEWSWIRE) -- Summit Therapeutics Inc. (NASDAQ: SMMT) (“Summit,” “we,” or the “Company”) and its product candidate, ridinilazole, will have an oral podium...
The Biocodex Microbiota Foundation calls for Canadian proposals to study the microbiome’s role in health and diseases
August 04, 2022 10:26 ET
|
Biocodex Canada
The Biocodex Microbiota Foundation is looking for academics and scientists in Canada to apply for a €25,000 research grant aimed at helping advance the study of the gut microbiome MONTREAL, Aug. 04,...
Summit Therapeutics Inc Reports Financial Results and Operational Progress for the First Quarter Ended March 31, 2022
May 11, 2022 16:30 ET
|
Summit Therapeutics Inc.
Cambridge, MA, May 11, 2022 (GLOBE NEWSWIRE) -- Summit Therapeutics Inc. (NASDAQ: SMMT) ("Summit," "we," or the "Company") today reports its financial results and provides an update on operational...
Taconic Biosciences and Biomodels Establish Microbiome Initiative
April 26, 2022 09:00 ET
|
Taconic Biosciences
RENSSELAER, N.Y., April 26, 2022 (GLOBE NEWSWIRE) -- Taconic Biosciences, a global leader in providing drug discovery animal model solutions, and Biomodels, a provider of contract research services...